Roshanbin, S.; Julku, U.; Xiong, M.; Eriksson, J.; Masliah, E.; Hultqvist, G.; Bergström, J.; Ingelsson, M.; Syvänen, S.; Sehlin, D.
Reduction of αSYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody. Pharmaceutics 2022, 14, 1412.
https://doi.org/10.3390/pharmaceutics14071412
AMA Style
Roshanbin S, Julku U, Xiong M, Eriksson J, Masliah E, Hultqvist G, Bergström J, Ingelsson M, Syvänen S, Sehlin D.
Reduction of αSYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody. Pharmaceutics. 2022; 14(7):1412.
https://doi.org/10.3390/pharmaceutics14071412
Chicago/Turabian Style
Roshanbin, Sahar, Ulrika Julku, Mengfei Xiong, Jonas Eriksson, Eliezer Masliah, Greta Hultqvist, Joakim Bergström, Martin Ingelsson, Stina Syvänen, and Dag Sehlin.
2022. "Reduction of αSYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody" Pharmaceutics 14, no. 7: 1412.
https://doi.org/10.3390/pharmaceutics14071412
APA Style
Roshanbin, S., Julku, U., Xiong, M., Eriksson, J., Masliah, E., Hultqvist, G., Bergström, J., Ingelsson, M., Syvänen, S., & Sehlin, D.
(2022). Reduction of αSYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody. Pharmaceutics, 14(7), 1412.
https://doi.org/10.3390/pharmaceutics14071412